

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medtide Inc.

泰德醫藥(浙江)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3880)

INSIDE INFORMATION

ISSUANCE OF FILING NOTICE BY CSRC FOR THE H SHARE FULL CIRCULATION APPLICATION OF THE COMPANY

This announcement is made by Medtide Inc. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules, namely under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

Reference is made to the announcement of the Company dated July 27, 2025 in relation to acceptance by the CSRC of application for the Company’s H Share Full Circulation plan (the “**Announcement**”). Unless otherwise defined in this announcement, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that the Company received a filing notice issued by the CSRC (the “**Filing Notice**”) in respect of the Conversion and Listing on February 5, 2026. According to the Filing Notice, the CSRC filing in relation to the Conversion and Listing has been completed, and if the Company does not complete share conversion within 12 months from the date of the issuance of the Filing Notice but intends to proceed, an updated filing to the CSRC would be required.

As at the date of this announcement, details of the implementation plan of the Conversion and Listing have not been finalized. The Company will make further announcement(s) on the progress of the Conversion and Listing in accordance with the requirements of the Listing Rules and applicable laws and regulations.

The H Share Full Circulation, the Conversion and Listing are subject to other relevant procedures as required by the CSRC, the Stock Exchange and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Medtide Inc.
泰德醫藥(浙江)股份有限公司
Dr. Xu Qi
Chairwoman and Executive Director

Hong Kong, February 5, 2026

As at the date of this announcement, the executive directors of the Company are Dr. Xu Qi, Dr. Li Xiang, Ms. Li Xiangli, Ms. Cheng Tao and Ms. Li Lingmei; the non-executive director of the Company is Mr. Wu Yihui; and the independent non-executive directors of the Company are Dr. Yu Cheung Hoi, Dr. Zhu Xun and Mr. Xia Xinsheng.